Advertisement

Topics

Trillium Therapeutics Reports Second Quarter 2017 Financial and Operating Results / Clinical responses observed in Phase 1 trial of TTI-621; Scope of trial expanded, including dose-intensification strategy; $39 million capital raise; cash and marketable

07:04 EDT 11 Aug 2017 | FinanzNachrichten

TORONTO, ONTARIO -- (Marketwired) -- 08/11/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...

Original Article: Trillium Therapeutics Reports Second Quarter 2017 Financial and Operating Results / Clinical responses observed in Phase 1 trial of TTI-621; Scope of trial expanded, including dose-intensification strategy; $39 million capital raise; cash and marketable

NEXT ARTICLE

More From BioPortfolio on "Trillium Therapeutics Reports Second Quarter 2017 Financial and Operating Results / Clinical responses observed in Phase 1 trial of TTI-621; Scope of trial expanded, including dose-intensification strategy; $39 million capital raise; cash and marketable"

Quick Search
Advertisement
 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...